Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath M, Schett G (2021)
Publication Type: Journal article, Review article
Publication year: 2021
Book Volume: 3
Pages Range: e724-e736
Journal Issue: 10
DOI: 10.1016/S2665-9913(21)00247-2
At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory diseases were considered to be at high risk for SARS-CoV-2 infection and the development of severe COVID-19. Data collected over the past year, however, suggest that a diagnosis of inflammatory arthritis, psoriasis, or inflammatory bowel diseases does not increase risk for SARS-CoV-2 infection or severe COVID-19 compared with people without these diseases. Furthermore, substantial data suggest that certain medications frequently used in patients with immune-mediated inflammatory diseases, in particular cytokine inhibitors, might even lower the risk for severe COVID-19. Conversely, glucocorticoids and potentially B-cell-depleting treatments seem to worsen COVID-19 outcomes. Additionally, the first data on SARS-CoV-2 vaccination in patients with these diseases suggest that tolerability of vaccination in patients with immune-mediated inflammatory diseases is good, although the immune response to vaccination can be somewhat reduced in this patient group, particularly those taking methotrexate or CD20-targeted treatment.
APA:
Fagni, F., Simon, D., Tascilar, K., Schoenau, V., Sticherling, M., Neurath, M., & Schett, G. (2021). COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. The Lancet Rheumatology, 3(10), e724-e736. https://dx.doi.org/10.1016/S2665-9913(21)00247-2
MLA:
Fagni, Filippo, et al. "COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses." The Lancet Rheumatology 3.10 (2021): e724-e736.
BibTeX: Download